---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-024955"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T20:11:00.425932+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxart receives stop work order from BARDA on Phase 2b oral COVID-19 vaccine trial

## Summary
- ATI/BARDA directed Vaxart to stop all work on Project Agreement RRPV-24-04-NGVx-003 for oral COVID-19 vaccine.
- Company may only continue follow-up for already dosed participants in the 10,000-person cohort; enrollment about half complete.
- No reason provided; DSMB had determined on July 14 that the study could proceed without modification.
- Company expects a follow-up notice with further details; no additional funding or termination decision announced.

## SEC filing metadata
- accession: 0001437749-25-024955
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925024955/0001437749-25-024955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925024955/vxrt20250805_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-024955
- JSON: https://secwatch.observer/filing/0001437749-25-024955.json
- Plain text: https://secwatch.observer/filing/0001437749-25-024955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.